Vivos Therapeutics Analyst Ratings
Vivos Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/17/2023 | 42.86% | Ascendiant Capital | → $2.5 | Initiates Coverage On | → Buy |
| 08/13/2021 | 471.43% | Roth Capital | $11 → $10 | Maintains | Buy |
| 05/18/2021 | 528.57% | Roth Capital | $12 → $11 | Maintains | Buy |
| 01/11/2021 | 585.71% | Craig-Hallum | → $12 | Initiates Coverage On | → Buy |
| 01/05/2021 | 585.71% | Roth Capital | → $12 | Initiates Coverage On | → Buy |
| 日期 | 上/下行 | 分析師公司 | 价格目標變更 | 評級變更 | 上一頁/目前評分 |
|---|---|---|---|---|---|
| 01/17/2023 | 42.86% | 上升資本 | → 2.5 美元 | 啟動覆蓋範圍 | → 購買 |
| 2021 年 8 月 13 日 | 471.43% | 羅斯資本 | 十一元 → 十美元 | 維護 | 購買 |
| 2021 年 5 月 18 日 | 528.57% | 羅斯資本 | 十二美元 → 11 美元 | 維護 | 購買 |
| 2021 年 11 月 1 日 | 585.71% | 克雷格哈勒姆 | → 十二美元 | 啟動覆蓋範圍 | → 購買 |
| 2021 年 5 月 1 日 | 585.71% | 羅斯資本 | → 十二美元 | 啟動覆蓋範圍 | → 購買 |
What is the target price for Vivos Therapeutics (VVOS)?
活沃斯治療（VVOS）的目標價格是多少？
The latest price target for Vivos Therapeutics (NASDAQ: VVOS) was reported by Ascendiant Capital on January 17, 2023. The analyst firm set a price target for $2.50 expecting VVOS to rise to within 12 months (a possible 42.86% upside). 1 analyst firms have reported ratings in the last year.
上升資本於 2023 年 1 月 17 日報導了 Vivos 治療（納斯達克股票代碼：VVOS）的最新價格目標。該分析師公司設定了 2.50 美元的價格目標，預計 VVOS 將在 12 個月內上升（可能是 42.86％ 的上升空間）。1 家分析師公司在去年報告了評級。
What is the most recent analyst rating for Vivos Therapeutics (VVOS)?
Vivos 治療（VVOS）的最新分析師評分是什麼？
The latest analyst rating for Vivos Therapeutics (NASDAQ: VVOS) was provided by Ascendiant Capital, and Vivos Therapeutics initiated their buy rating.
Vivos 治療（納斯達克股票代碼：VVOS）的最新分析師評級由上升資本提供，Vivos 治療學發起了他們的買入評級。
When is the next analyst rating going to be posted or updated for Vivos Therapeutics (VVOS)?
VIVOS 治療（VVOS）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vivos Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vivos Therapeutics was filed on January 17, 2023 so you should expect the next rating to be made available sometime around January 17, 2024.
分析師在進行廣泛的研究後獲得了股票評級，其中包括通過公共財務報表，與 Vivos Therapertics 的高管和客戶交談以及收聽盈利電話會議。大多數分析師每三個月這樣做一次，因此您應該每年每家公司獲得 4 個評級。Vivos 治療的最後一個評分於 2023 年 1 月 17 日提交，因此您應該期望下一個評分將在 2024 年 1 月 17 日左右的某個時候提供。
Is the Analyst Rating Vivos Therapeutics (VVOS) correct?
分析師評級 Vivos 治療（VVOS）是否正確？
While ratings are subjective and will change, the latest Vivos Therapeutics (VVOS) rating was a initiated with a price target of $0.00 to $2.50. The current price Vivos Therapeutics (VVOS) is trading at is $1.75, which is within the analyst's predicted range.
雖然評級是主觀的並且會發生變化，但最新的 Vivos 治療（VVOS）評級是開始的，目標價格為 0.00 美元至 2.50 美元。目前的價格 Vivos 治療（VVOS）的交易價格為 1.75 美元，在分析師的預測範圍內。